Research has shown that hepatic lipid accumulation can be decreased by downregulating GAS5, indicating that this may be a promising therapeutic strategy for how NAFLD is managed [23]. The gene discussed is GAS5; the disease is metabolic dysfunction-associated steatotic liver disease.